Zekayi KUTLUBAY, Server SERDAROĞLU, Ayşegül SEVİM KEÇİCİ, Suphi VEHİD, Övgü AYDIN

Assessment of treatment efficacy of diphenylcyclopropenone (DPCP) for alopecia areata

Background/aim: Alopecia areata (AA) is an inflammatory disease with a genetic and autoimmune basis. Herein, it was aimed to study the efficacy and safety of an immunomodulatory therapeutic agent, diphenylcyclopropenone, while manifesting its association with histopathological features, prognostic factors, and side effects. Materials and methods: In this retrospective study, 98 patients (60 males, 38 females) with alopecia, who were referred to the Hair Disease Polyclinic at the Department of Dermatology, between 2011 and 2015, were included. Together with medical histories and dermatological examinations, a skin biopsy for histopathological examination was conducted for all of the patients prior to therapy. Therapeutic success was evaluated on the basis of the hair regrowth percentage. Results: Regarding the overall treatment success, 33 (34%) patients had complete response, 16 (16%) had partial response (between 50% and 99%), 27 (28%) had minimal response (between 1% and 49%), and 22 (22%) were nonresponders. Both sexs were equally represented in the outcome. Conclusions: There was a significant relation between the severity of alopecia and the treatment outcome (P = 0.038). Patients with AA had significantly better response when compared to those with alopecia totalis and universalis. There was no statistically significant relation with other parameters, such as disease duration, age, sex, atopy history, age of onset, and histopathological features.

PDF

___

1. Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N et al. Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. Journal of American Academy of Dermatology 2018; 78(1):1-12. doi:10.1016/j. jaad.2017.04.1141
2. Magen E, Chikovani T, Waitman DA, Kahan NR. Association of alopecia areata with atopic dermatitis and chronic spontaneous urticaria. Allergy Asthma Proceedings 2018; 39 (2): 96-102. doi:10.2500/aap.2018.39.4114
3. Happle R, Hausen BM, Wiesner-Menzel L. Diphencyprone in the treatment of alopecia areata. Acta Dermatology and Venereology 1983; 63 (2): 49-52.
4. Ito T, Aoshima M, Ito N, Uchiyama I, Sakamoto K et al. Combination therapy with oral PUVA and corticosteroid for recalcitrant alopecia areata. Archieves of Dermatological Research 2009; 301 (5): 373-80. doi:10.1007/s00403-009-0936-8
5. Rallis E, Nasiopoulou A, Kouskoukis C, Roussaki-Schulze A, Koumantaki E et al. Oral administration of cyclosporin A in patients with severe alopecia areata. International Journal of Tissue Reactions 2005; 27 (3): 107-110. doi:10.1016/S1578- 2190(09)70063-0
6. Smith JR, Akin RS, Wells MJ. Alopecia areata treated with efalizumab: a case with significant hair re-growth after longterm therapy. Journal of Drugs in Dermatology 2009; 8 (8): 758- 760.
7. Strober BE, Siu K, Alexis AF, Kim G, Washenik K et al. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. Journal of American Academy of Dermatology 2005; 52 (6): 1082-1084. doi:10.1016/j.jaad.2005.03.039
8. D’Ovidio R. Alopecia areata: news of diagnosis, pathogenesis, and treatment. Italian Journal of Dermatology and Venereology 2014; 149 (1): 25-45. doi:10.4103/ijt.ijt_99_17
9. Holzer AM, Kaplan LL, Lewis WR. Haptens as drugs: contact allergens are powerful topical immunomodulators. Journal of Drugs in Dermatology 2006; 5 (5): 410-416.
10. Wilkerson MG, Connor TH, Henkin J, Wilkin JK, Matney TS. Assessment of diphenylcyclopropenone for photochemically induced mutagenicity in the Ames assay. Journal of American Academy of Dermatology 1987; 17 (4): 606-611. doi:10.1016/ S0190-9622(87)70244-8
11. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part II. Treatment. Journal of American Academy of Dermatology 2010; 62 (2): 203-204. doi:10.1016/j. jaad.2009.10.031
12. Breslow R, Haynie R, Mirra J. The synthesis of diphenylcyclopropenone. Journal of the American Chemical Society 1959; 81 (3): 247-248.
13. Simonetti O, Lucarini G, Bernardini ML, Simoncini C, Biagini G et al. Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study. British Journal of Dermatology 2004; 150 (5): 940-948. doi:10.1111/j.1365-2133.2004.05881.x
14. Gulati N, Suarez-Farninas M, Gilleaudeau P. Topical DPCP induces distinct early and late phase cellular immune reactions in human skin. Journal of Investigative Dermatology 2013; 133 (9): 159-190. doi:10.1038/jid.2014.196
15. Shapiro J. Topical immunotherapy in the treatment of chronic severe alopecia areata. Dermatological Clinics 1993; 11 (3): 611-617. doi:10.1016/S0733-8635(18)30254-7
16. Shapiro J, Tan J, Tron V. Treatment of severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation. Journal of Investigative Dermatology 1995; 104 (5): 36. doi:10.1038/jid.1995.54
17. Orecchia G, Perfetti L, Borroni G, Rabbiosi G. Photochemotherapy plus squaric acid dibutylester in alopecia areata treatment. Dermatologica 1990; 181 (2): 167. doi:10.1159/000247914
18. Berth-Jones J, Hutchinson P. Treatment of alopecia totalis with a combination of inosine pranobex and diphencyprone compared to each treatment alone. Clinical and Experimental Dermatology 1991; 16 (3): 172. doi:10.1111/j.1365-2230.1991. tb00339.x
19. Sutherland L, Laschinger M, Syed ZU, Gaspari A. Treatment of alopecia areata with topical sensitizer. Dermatitis 2015; 26 (1): 26-31. doi:10.1097/DER.0000000000000094
20. Van der Steen PH, Van Baar HM, Happle R, Boezeman JB, Perret CM. Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone. Journal of American Academy of Dermatology 1991; 24 (2 pt 1): 227-230. doi:10.1016/0190-9622(91)70032-w
21. Ohlmeier MC, Traupe H, Luger TA, Böhm M. Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata-a large retrospective study on 142 patients with a self-controlled design. Journal of European Academy of Dermatology and Venereology 2012; 26 (4):503-7. doi:10.1111/ j.1468-3083.2011.04114.x
22. Durdu M, Özcan D, Baba M, Seçkin D. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series. Journal of American Academy of Dermatology 2015; 72 (4:640-650. doi:10.1016/j. jaad.2015.01.008
23. Cotellessa C, Peris K, Caracciolo E, Mordenti C, Chimenti S. The use of topical diphencyclopropenone for the treatment of extensive alopecia areata. Journal of American Academy of Dermatology 2001; 44 (1): 73-76. doi:10.1067/mjd.2001.109309
24. Ito T, Ito N, Saatoff M, Hashizume H, Fukamizu H. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. Journal of Investigative Dermatology 2008; 128 (5): 1196-1206. doi:10.1038/sj.jid.5701183
25. Ito T, Ito N, Bettermann A, Tokura Y, Takigawa M. Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair folicle as a model. American Journal of Pathology 2004; 164 (2): 623-634. doi:10.1016/S0002- 9440(10)63151-3
26. Ro B. Alopecia areata in Korea. Journal of Dermatology 1995; 22 (11): 858-864. doi:10.1111/j.1346-8138.1995.tb03936.x
27. Weise K, Kretzschmar L, John SM, Hamm H. Topical immunotherapy in alopecia areata: anamnestic for the treatment of extensive alopecia areata. Journal of American Academy of Dermatology 1996; 192 (2): 129-133. doi:10.1159/000246337
28. Iijima S, Otsuka F. Prognostic factors for clinical response of alopecia areata to topical immunotherapy with squaric acid dibutylester. Archieves of Dermatology 1997; 133 (4): 539-540. doi:10.1001/archderm.1997.03890400145035
29. Donovan J, Salsberg J. The safety and efficacy of diphencyprone for the treatment of alopecia areata in children. Archieves of Dermatology 2012; 148: 148 (9):1084-1085. doi: 10.1001/ archdermatol.2012.1622